Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specialising in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced on Thursday that it has been honoured with multiple awards by Top Workplaces and the US News & World Report 2024-2025 ratings.
Top Workplaces has added Zynex to its 2024 Top Workplaces - Manufacturing list. US News & World Report has also offered Zynex with three awards under its 'Best Companies to Work For' in 2024-2025 ratings, including 'Best in Pharmaceuticals and Health Products', 'Best Companies' and 'Best in the West'.
Thomas Sandgaard, Founder, Chairman, and CEO of Zynex, said, 'We are privileged to be recognized by both Top Workplaces and US News & World Report, recognizing the emphasis we place on our team by developing leaders and sustaining employee well-being. We continue to place a high priority on supporting our employees to advance in their careers and maintain work/life balances. By improving on our team's health, benefits and comfort, we can in turn empower them to accelerate progress on business goals including order growth, FDA approvals of next-generation devices, and new therapy products.'
Bonesupport submits FDA application for CERAMENT V
DDL opens new GMP laboratory for drug-device combination product testing
Abbott receives CE Mark for Volt Pulsed Field Ablation System to treat atrial fibrillation
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Qlife secures UK approval to initiate clinical trial for Egoo Phe System
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
Femasys receives CE mark approval for FemBloc delivery system in Europe
Abbott announces quarterly common dividend
Aiforia secures IVDR certification for expanded AI-powered cancer diagnostics in Europe
Limaca Medical launches Precision-GI endoscopic automated motorised EUS biopsy device in US
Owens & Minor launches ByramConnect digital health platform for diabetes management
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay